Triple
T6718914
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | SIX Swiss Exchange |
E153343
|
entity |
| Predicate | listsCompany |
P71780
|
FINISHED |
| Object | Novartis |
E141505
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Novartis | Statement: [SIX Swiss Exchange, listsCompany, Novartis]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Novartis Context triple: [SIX Swiss Exchange, listsCompany, Novartis]
-
A.
Novartis
chosen
Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
-
B.
Roche
Roche is a common surname of French origin borne by various notable individuals across fields such as architecture, politics, and the arts.
-
C.
Roche
Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
-
D.
Sandoz
Sandoz is a historic Swiss pharmaceutical company best known as a predecessor of Novartis and a major player in generic medicines.
-
E.
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company known for developing and manufacturing innovative medicines in areas such as oncology, immunology, and cardiovascular disease.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c68809b4608190a2509ddb5ab87f05 |
completed | March 27, 2026, 1:37 p.m. |
| NER | Named-entity recognition | batch_69c6d7c94bac8190ae4b236d1b04bec9 |
completed | March 27, 2026, 7:17 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c70afa805c819098312fc0d06ec115 |
completed | March 27, 2026, 10:55 p.m. |
Created at: March 27, 2026, 2:07 p.m.